Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAGBiotechnology
+$2.32 today
- Market cap
- $1.83B
- Beta
- 0.00
Volume 0.30M
Average 0.34M
COAG Total Current Liabilities
All obligations due within one year.
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ: COAG
Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total current liabilities of $12.94M in Q2 FY2026
Q2 FY2026 total current liabilities was $12.94M.
Context
- Total current liabilities amounted to 2.8% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 10.68M USD
- Year-over-year change
- —
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.68M | — |
Total Current Liabilities vs competitors
How COAG compares with its peers on the latest reported figures
- COAG's Jun 2026 total current liabilities of $12.94M is the 4th highest of the 5 companies compared; the peer median is $29.09M.
- Total current liabilities amounts to 2.8% of total assets for COAG, versus a peer median of 6.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $59.2M | +63.0% | -6.1% | 7.6% | |
IRONDisc Medicine, Inc. | Sep 2026 | $34.36M | +28.5% | +17.5% | 4.9% |
DMRADamora Therapeutics, Inc. | Mar 2026 | $23.81M | +1435.3% | +21.8% | 4.4% |
COAGHemab Therapeutics Holdings, Inc. Common Stock | Jun 2026 | $12.94M | — | — | 2.8% |
| Mar 2026 | $4.14M | +5.9% | -26.7% | 7.6% | |
| Peer median (excluding COAG) | $29.09M | +45.8% | +5.7% | 6.3% | |
Competitors are the stored peer set for COAG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
Intrinsic Alpha fair value
Locked
Current Price
$39.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.